Wan-Jen Hong joined Imago in May 2021 as the Chief Medical Officer. Prior to joining Imago, Dr. Hong was a Group Medical Director at Genentech, where she spent 7 years in the late-stage clinical development group. She worked on the development of several molecules across multiple indications in hematology/oncology and played a leading role in the indication expansion for venetoclax in AML.
Dr. Hong received a B.S in chemical engineering and biology from Massachusetts Institute of Technology and a M.D. from Stanford University. She completed her clinical training in internal medicine and hematology/oncology at Stanford University and is an adjunct clinical faculty member in the Division of Hematology at Stanford.